Complexities of adjuvant endocrine therapy in young premenopausal women

ONCOLOGY

Volumn 23, Issue 6, 2009, Pages

  Henry, N Lynn ^a   Griggs, Jennifer J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CITALOPRAM; CYTOCHROME P450 2D6; DULOXETINE; ENDOXIFEN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOXETINE; GABAPENTIN; GONADORELIN AGONIST; PAROXETINE; SERTRALINE; TAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG; VENLAFAXINE;

ADJUVANT THERAPY; AMENORRHEA; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; FEMALE; GENETIC ANALYSIS; GENOTYPE; HORMONAL THERAPY; HOT FLUSH; HUMAN; IMMUNOASSAY; MASS SPECTROMETRY; MEDICAL DECISION MAKING; MENOPAUSAL SYNDROME; NOTE; OVARY INSUFFICIENCY; PATIENT CARE; PHYSICIAN; PREMENOPAUSE; SYSTEMIC THERAPY; TREATMENT INDICATION;

ADULT; AMENORRHEA; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC SCREENING; GENOTYPE; HUMANS; OVARY; PREMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 67650459912     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (20)

1. Li CI, Daling JR, Malone KE: Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 21:28-34, 2003.
2. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005. (Pubitemid 40719106)
3. Dowsett M, Haynes BP: Hormonal effects of aromatase inhibitors: Focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol 86:255-263, 2003. (Pubitemid 37412564)
4. Carlson RW, Schurman CM, Rivera E, et al: Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/metastatic breast cancer (abstract 6052). Breast Cancer Res Treat 88(suppl 1):S237, 2004.
5. Dowsett M, Folkerd E: Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res 7:1-4, 2005. (Pubitemid 40214529)
6. Johannessen DC, Engan T, Di Salle E, et al: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clin Cancer Res 3:1101-1108, 1997. (Pubitemid 27319756)
7. Nelson RE, Grebe SK, DJ OK, et al: Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem 50:373-384, 2004. (Pubitemid 38156379)
8. Kushnir MM, Rockwood AL, Bergquist J, et al: High-sensitivity tandem mass spectrometry assay for serum estrone and estradiol. Am J Clin Pathol 129:530-539, 2008. (Pubitemid 352029271)
9. Braverman AS, Sawhney H, Tendler A, et al: Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT)-induced amenorrhea in breast cancer (BC) (abstract 164). Proc Am Soc Clin Oncol 21, 2002.
10. Smith IE, Dowsett M, Yap Y-S, et al: Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines. J Clin Oncol 24:2444-2447, 2006. (Pubitemid 46630620)
11. Stearns V, Johnson MD, Rae JM, et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764, 2003. (Pubitemid 38008898)
12. Johnson MD, Zuo H, Lee KH, et al: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159, 2004. (Pubitemid 38987269)
13. Jin Y, Desta Z, Stearns V, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39, 2005.
14. Goetz MP, Rae JM, Suman VJ, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318, 2005. (Pubitemid 46260189)
15. Goetz MP, Suman V, Ames M, et al: Tamoxifen pharmacogenetics of CYP2D6, CYP2C19, and SULT1A1: Long term follow-up of the North Central Cancer Treatment Group 89-30-52 adjuvant trial (abstract 6037). Cancer Res 69(suppl), 2009.
16. Lim HS, Ju Lee H, Seok Lee K, et al: Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25:3837-3845, 2007.
17. Schroth W, Antoniadou L, Fritz P, et al: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193, 2007. (Pubitemid 350232249)
18. Wegman P, Elingarami S, Carstensen J, et al: Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9:R7, 2007. (Pubitemid 350215154)
19. Wegman P, Vainikka L, Stal O, et al: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7:R284-R290, 2005.
20. Borges S, Desta Z, Li L, et al: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74, 2006. (Pubitemid 43946844)